Atrium Therapeutics (RNA) investor relations material

Executive summary

• Completed spin-off from Avidity Biosciences in February 2026, becoming an independent, publicly traded company on Nasdaq focused on RNA therapeutics for cardiomyopathies.

• Lead programs ATR 1072 and ATR 1086 target PRKAG2 syndrome and PLN cardiomyopathy, both in preclinical development with IND filings expected in 2H 2026 and 2027, respectively.

• Achieved a $15 million milestone payment from Bristol Myers Squibb for delivering a development candidate.

• Entered into key collaboration and license agreements with Bristol Myers Squibb and Eli Lilly, providing milestone and research funding.

Financial highlights

• Collaboration revenue for Q1 2026 was $19.6 million, primarily from a $15 million BMS milestone, up from $1.6 million in Q1 2025.

• Net loss for Q1 2026 was $16.6 million, with basic and diluted net loss per share of $0.97.

• Cash and cash equivalents as of March 31, 2026, were $267.8 million, following a $270 million capitalization at spin-off.

• R&D expenses were $16.7 million and G&A expenses totaled $20.3 million in Q1 2026.

Outlook and guidance

• Plans to submit IND application for ATR 1072 in 2H 2026 and for ATR 1086 in 2027, with enabling studies starting in 2026.

• Existing cash is expected to fund operations for at least 12 months and through key clinical proof-of-concept milestones.

• Anticipates continued operating losses as R&D and infrastructure investments increase.

• Plans to finance future needs through equity, debt, or additional collaborations.